Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20250994 | 0.89 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL23326499 | 0.86 | STING1 (0.39) | STING1 | |
| SCHEMBL23326498 | 0.86 | STING1 (0.39) | STING1 | |
| SCHEMBL20773596 | 0.81 | KDM4E (0.43) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL19880310 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL1936920 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL25496217 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL23350694 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL19509409 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL18954971 | 0.80 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267844-B2 | Spirothietane nucleosides | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-08 | — | — | US | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267844-B2 | Spirothietane nucleosides | SAMHD1, SLC28A1, SLC28A2 | KDM4E 2709/4885TAS1R3 3063/4885TAS1R1 3410/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | KDM4E 2709/4885TAS1R3 3063/4885TAS1R1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.